Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II.

Jeger RV, Pfisterer M, Vogt DR, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz DJ, Pedrazzini G, Vuilliomenet A, Weilenmann D, Rickli H, Hansen KW, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Kaiser C.

PLoS One. 2019 Jan 15;14(1):e0210821. doi: 10.1371/journal.pone.0210821. eCollection 2019.

2.

Haemodynamic mechanisms and long-term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement.

Weber L, Rickli H, Haager PK, Joerg L, Weilenmann D, Brenner R, Taramasso M, Baier P, Maisano F, Maeder MT.

Eur J Heart Fail. 2019 Feb;21(2):172-181. doi: 10.1002/ejhf.1322. Epub 2018 Oct 17.

PMID:
30328215
3.

Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.

Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, Schreiber M, Mahfoud F, Linke A, Stephan FP, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators.

Lancet. 2018 Sep 8;392(10150):849-856. doi: 10.1016/S0140-6736(18)31719-7. Epub 2018 Aug 28.

PMID:
30170854
4.

Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.

Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Muller O, Moarof I, Siontis GCM, Cook S, Weilenmann D, Kaiser C, Cuculi F, Hunziker L, Eberli FR, Jüni P, Windecker S.

Lancet. 2018 Sep 1;392(10149):737-746. doi: 10.1016/S0140-6736(18)31715-X. Epub 2018 Aug 28.

PMID:
30170848
5.

[A Rare Cause for Transient Aphasia after Conorary Angiography].

Schilling C, Weilenmann D, Diener S, Hundsberger T.

Praxis (Bern 1994). 2018 Apr;107(9-10):531-534. doi: 10.1024/1661-8157/a002977. German. No abstract available.

PMID:
29690845
6.

Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism.

Coquoz N, Weilenmann D, Stolz D, Popov V, Azzola A, Fellrath JM, Stricker H, Pagnamenta A, Ott S, Ulrich S, Györik S, Pasquier J, Aubert JD.

Eur Respir J. 2018 Apr 4;51(4). pii: 1702505. doi: 10.1183/13993003.02505-2017. Print 2018 Apr.

PMID:
29563171
7.

Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2.

Gilgen N, Farah A, Scheller B, Ohlow MA, Mangner N, Weilenmann D, Wöhrle J, Jamshidi P, Leibundgut G, Möbius-Winkler S, Zweiker R, Krackhardt F, Butter C, Bruch L, Kaiser C, Hoffmann A, Rickenbacher P, Mueller C, Stephan FP, Coslovsky M, Jeger R; BASKET-SMALL 2 Investigators.

Clin Cardiol. 2018 May;41(5):569-575. doi: 10.1002/clc.22942. Epub 2018 May 10.

8.

A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.

Iglesias JF, Muller O, Zaugg S, Roffi M, Kurz DJ, Vuilliomenet A, Weilenmann D, Kaiser C, Tapponnier M, Heg D, Valgimigli M, Eeckhout E, Jüni P, Windecker S, Pilgrim T.

EuroIntervention. 2018 Aug 20;14(6):692-699. doi: 10.4244/EIJ-D-17-00734.

9.

Pulmonary hypertension in stiff left atrial syndrome: pathogenesis and treatment in one.

Maeder MT, Nägele R, Rohner P, Weilenmann D.

ESC Heart Fail. 2018 Feb;5(1):189-192. doi: 10.1002/ehf2.12234. Epub 2017 Nov 8.

10.

Switzerland: coronary and structural heart interventions from 2010 to 2015.

Rigamonti F, Fahrni G, Maeder M, Cook S, Weilenmann D, Wenaweser P, Röthlisberger C, Corti R, Rickli H, Kaiser C, Roffi M.

EuroIntervention. 2017 May 15;13(Z):Z75-Z79. doi: 10.4244/EIJ-D-16-00828.

11.

Pulmonary hypertension associated with left-sided heart disease.

Maeder MT, Schoch OD, Kleiner R, Joerg L, Weilenmann D, Swiss Society For Pulmonary Hypertension.

Swiss Med Wkly. 2017 Jan 17;147:w14395. doi: 10.4414/smw.2017.14395. eCollection 2017. Review.

12.

Impact of Patient and Lesion Complexity on Long-Term Outcomes Following Coronary Revascularization With New-Generation Drug-Eluting Stents.

Koskinas KC, Taniwaki M, Rigamonti F, Heg D, Roffi M, Tüller D, Muller O, Vuillomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Jüni P, Windecker S, Pilgrim T.

Am J Cardiol. 2017 Feb 15;119(4):501-507. doi: 10.1016/j.amjcard.2016.10.038. Epub 2016 Nov 16.

PMID:
27923461
13.

Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial.

Franzone A, Taniwaki M, Rigamonti F, Heg D, Piccolo R, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Jüni P, Windecker S, Pilgrim T.

EuroIntervention. 2016 Aug 5;12(5):e595-604. doi: 10.4244/EIJV12I5A99.

14.

Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: Insights From the 2-Year Follow-Up of the BIOSCIENCE Trial.

Piccolo R, Heg D, Franzone A, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Iglesias JF, Windecker S, Pilgrim T.

JACC Cardiovasc Interv. 2016 May 9;9(9):981-3. doi: 10.1016/j.jcin.2016.02.044. No abstract available.

15.

Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.

Zbinden R, Piccolo R, Heg D, Roffi M, Kurz DJ, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Franzone A, Eberli F, Jüni P, Windecker S, Pilgrim T.

J Am Heart Assoc. 2016 Mar 15;5(3):e003255. doi: 10.1161/JAHA.116.003255.

16.

Spontaneous Coronary Artery Dissection: Angiographic Follow-Up and Long-Term Clinical Outcome in a Predominantly Medically Treated Population.

Rogowski S, Maeder MT, Weilenmann D, Haager PK, Ammann P, Rohner F, Joerg L, Rickli H.

Catheter Cardiovasc Interv. 2017 Jan;89(1):59-68. doi: 10.1002/ccd.26383. Epub 2015 Dec 28.

PMID:
26708825
17.

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.

Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab AA, Taniwaki M, Rigamonti F, Nietlispach F, Blöchlinger S, Wenaweser P, Jüni P, Windecker S.

EuroIntervention. 2016 Dec 10;12(11):e1343-e1354. doi: 10.4244/EIJY15M12_09.

18.

Severely worsening dyspnea after initiation of macitentan therapy for pulmonary arterial hypertension.

Maeder MT, Kleiner R, Weilenmann D.

Int J Cardiol. 2016 Jan 1;202:244-5. doi: 10.1016/j.ijcard.2015.08.132. Epub 2015 Sep 14. No abstract available.

PMID:
26402452
19.

Recurrent left anterior descending artery spasm causing transmural ischaemia treated with stenting.

Häfliger M, Weilenmann D, Rickli H, Maeder MT.

Eur Heart J. 2016 Jan 21;37(4):364. doi: 10.1093/eurheartj/ehv309. Epub 2015 Jul 18. No abstract available.

PMID:
26188213
20.

Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.

Franzone A, Pilgrim T, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Räber L, Stortecky S, Wenaweser P, Jüni P, Windecker S.

Circ Cardiovasc Interv. 2015 Jun;8(6). pii: e002319. doi: 10.1161/CIRCINTERVENTIONS.114.002319.

PMID:
26043895
21.

Long-term data from the Swiss pulmonary hypertension registry.

Mueller-Mottet S, Stricker H, Domenighetti G, Azzola A, Geiser T, Schwerzmann M, Weilenmann D, Schoch O, Fellrath JM, Rochat T, Lador F, Beghetti M, Nicod L, Aubert JD, Popov V, Speich R, Keusch S, Hasler E, Huber LC, Grendelmeier P, Tamm M, Ulrich S.

Respiration. 2015;89(2):127-40. doi: 10.1159/000370125. Epub 2015 Jan 31. Erratum in: Respiration. 2015;89(5)373. Domeninghetti, Guido [corrected to Domenighetti, Guido.

22.

Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.

Kaiser C, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz DJ, Pedrazzini G, Moccetti T, Rickli H, Weilenmann D, Vuillomenet A, Steiner M, Von Felten S, Vogt DR, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M; BASKET-PROVE II study group.

Circulation. 2015 Jan 6;131(1):74-81. doi: 10.1161/CIRCULATIONAHA.114.013520. Epub 2014 Nov 19.

PMID:
25411159
23.

Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.

Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S.

Lancet. 2014 Dec 13;384(9960):2111-22. doi: 10.1016/S0140-6736(14)61038-2. Epub 2014 Sep 1.

PMID:
25189359
24.

Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial.

Pilgrim T, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Heg D, Jüni P, Windecker S.

Am Heart J. 2014 Sep;168(3):256-61. doi: 10.1016/j.ahj.2014.06.004. Epub 2014 Jun 6.

PMID:
25173535
25.

Use of optical coherence tomography in acute clinical settings.

Vollenbroich R, Maeder MT, Weilenmann D.

Int J Cardiol. 2014 Jun 15;174(2):e62-3. doi: 10.1016/j.ijcard.2014.04.095. Epub 2014 Apr 13. No abstract available.

PMID:
24780547
26.

Congestive heart failure related to antifungal therapy with itraconazole.

Vollenbroich R, Maeder MT, Weilenmann D.

Int J Cardiol. 2014;172(1):e170-1. doi: 10.1016/j.ijcard.2013.12.057. Epub 2013 Dec 29. No abstract available.

PMID:
24424341
27.

Clinical characteristics, sex hormones, and long-term follow-up in Swiss postmenopausal women presenting with Takotsubo cardiomyopathy.

Brenner R, Weilenmann D, Maeder MT, Jörg L, Bluzaite I, Rickli H, De Pasquale G, Ammann P.

Clin Cardiol. 2012 Jun;35(6):340-7. doi: 10.1002/clc.21986. Epub 2012 Apr 9.

28.

Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.

Häuptle R, Weilenmann D, Schneider T, Haile SR, Ammann P, Knellwolf C, Borovicka J.

Wien Med Wochenschr. 2012 Feb;162(3-4):67-73. doi: 10.1007/s10354-012-0056-5.

PMID:
22476595
29.

Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy.

Maeder MT, Rickli H, Pfisterer ME, Muzzarelli S, Ammann P, Fehr T, Hack D, Weilenmann D, Dieterle T, Kiencke S, Estlinbaum W, Brunner-La Rocca HP; TIME-CHF Investigators.

Am Heart J. 2012 Mar;163(3):407-14, 414.e1. doi: 10.1016/j.ahj.2011.12.003.

PMID:
22424011
30.

Constrictive pericarditis presenting as a large mediastinal mass causing functional tricuspid and pulmonary stenosis.

Ehl NF, Sündermann S, Geyer R, Thies S, Epp C, Weilenmann D, Falk V, Joerg L, Rickli H, Maeder MT.

Circulation. 2011 Nov 8;124(19):e487-91. doi: 10.1161/CIRCULATIONAHA.110.017830. No abstract available.

PMID:
22064960
31.

[Myocardial infarction during attempted suicide].

Tapernoux D, Weilenmann D, Diethelm M.

Dtsch Med Wochenschr. 2009 Feb;134(8):339-42. doi: 10.1055/s-0028-1124003. Epub 2009 Feb 10. German.

PMID:
19206051
32.

Long-term outcomes after intracoronary Beta-irradiation for in-stent restenosis in bare-metal stents.

Maeder MT, Pfisterer ME, Buser PT, Roser HW, Roth J, Weilenmann D, Nietlispach FP, Zellweger MJ, Amsler B, Kaiser CA.

J Invasive Cardiol. 2008 Apr;20(4):179-84.

PMID:
18398235
33.

B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure.

Maeder M, Wolber T, Rickli H, Myers J, Hack D, Riesen W, Weilenmann D, Ammann P.

Int J Cardiol. 2007 Sep 3;120(3):391-8. Epub 2006 Dec 19.

PMID:
17182129
34.

Integration of B-type natriuretic peptide levels with clinical data and exercise testing for predicting coronary artery disease.

Wolber T, Maeder M, Weilenmann D, Duru F, Bluzaite I, Riesen W, Rickli H, Ammann P.

Am J Cardiol. 2006 Sep 15;98(6):764-7. Epub 2006 Jul 28.

PMID:
16950181
35.

Images in cardiology: Rare case of pericarditis constrictiva.

Schlaudraff K, Weilenmann D, Künzli A.

Heart. 2005 Sep;91(9):1133. No abstract available.

36.

Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: an unpredictable and dose-independent phenomenon.

Bernheim A, Fatio R, Kiowski W, Weilenmann D, Rickli H, Brunner-La Rocca HP.

Transplantation. 2004 Apr 27;77(8):1181-5.

PMID:
15114081
37.

Prolonged oxygen uptake kinetics during low-intensity exercise are related to poor prognosis in patients with mild-to-moderate congestive heart failure.

Schalcher C, Rickli H, Brehm M, Weilenmann D, Oechslin E, Kiowski W, Brunner-La Rocca HP.

Chest. 2003 Aug;124(2):580-6.

PMID:
12907546
38.

Combining low-intensity and maximal exercise test results improves prognostic prediction in chronic heart failure.

Rickli H, Kiowski W, Brehm M, Weilenmann D, Schalcher C, Bernheim A, Oechslin E, Brunner-La Rocca HP.

J Am Coll Cardiol. 2003 Jul 2;42(1):116-22.

39.

Noninvasive evaluation of pulmonary capillary wedge pressure by BP response to the Valsalva maneuver.

Weilenmann D, Rickli H, Follath F, Kiowski W, Brunner-La Rocca HP.

Chest. 2002 Jul;122(1):140-5.

PMID:
12114349
40.

Clinical evaluation of a pacemaker algorithm that adjusts the pacing rate during sleep using activity variance.

Duru F, Bloch KE, Weilenmann D, Candinas R.

Pacing Clin Electrophysiol. 2000 Oct;23(10 Pt 1):1509-15.

PMID:
11060871
41.

Influence of acute exposure to high altitude and hypoxemia on ventricular stimulation thresholds in pacemaker patients.

Weilenmann D, Duru F, Schönbeck M, Schenk B, Zwicky P, Russi EW, Candinas R.

Pacing Clin Electrophysiol. 2000 Apr;23(4 Pt 1):512-5.

PMID:
10793443
42.

Importance of ventricular rate after mode switching during low intensity exercise as assessed by clinical symptoms and ventilatory gas exchange.

Brunner-La Rocca HP, Rickli H, Weilenmann D, Duru F, Candinas R.

Pacing Clin Electrophysiol. 2000 Jan;23(1):32-9.

PMID:
10666751
43.

Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure?

Brunner-La Rocca HP, Weilenmann D, Rickli H, Follath F, Kiowski W.

Chest. 1999 Oct;116(4):861-7.

PMID:
10531144
44.

Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure.

Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly FE, Candinas R, Follath F.

Am Heart J. 1999 Oct;138(4 Pt 1):654-62.

PMID:
10502210
45.

Prognostic significance of oxygen uptake kinetics during low level exercise in patients with heart failure.

Brunner-La Rocca HP, Weilenmann D, Schalcher C, Schlumpf M, Follath F, Candinas R, Kiowski W.

Am J Cardiol. 1999 Sep 15;84(6):741-4, A9.

PMID:
10498150
46.

Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events.

Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly FE, Follath F.

J Pharmacol Exp Ther. 1999 Apr;289(1):565-71.

PMID:
10087051
47.

Oxygen uptake kinetics during low level exercise in patients with heart failure: relation to neurohormones, peak oxygen consumption, and clinical findings.

Brunner-La Rocca HP, Weilenmann D, Follath F, Schlumpf M, Rickli H, Schalcher C, Maly FE, Candinas R, Kiowski W.

Heart. 1999 Feb;81(2):121-7.

48.

Activity-controlled circadian base rate.

Park E, Weilenmann D, Bloch K, Kueffner J, Bornzin G, Candinas R, Levine PA.

Pacing Clin Electrophysiol. 1998 Nov;21(11 Pt 2):2182-6.

PMID:
9825315
49.

Relative frequency of functional sympathetic and parasympathetic reinnervation after heart transplantation.

Brunner-La Rocca HP, Weilenmann D, Bracht C, Carli S, Schlumpf M, Follath F, Kiowski W.

J Heart Lung Transplant. 1998 Jul;17(7):725-8.

PMID:
9703239
50.

Atrioventricular block after administration of atropine in patients following cardiac transplantation.

Brunner-La Rocca HP, Kiowski W, Bracht C, Weilenmann D, Follath F.

Transplantation. 1997 Jun 27;63(12):1838-9.

PMID:
9210514

Supplemental Content

Loading ...
Support Center